The MedTech Research Reports
The current healthcare equity research landscape is full of noise and a lack of transparency. Our new MedTech research offering is revolutionizing the way investors track and analyze their MedTech positions with fast, accurate, and easy to use insights addressing key narratives in the space.
Finalized and settled full month estimates within two weeks of current month
Absolute Average Deltas as low as 0.8%
Gives accurate insights into category market share and new product launches
Digestible research reports and interactive dashboards
Prior to Edward’s (EW) weak 2Q24 earnings results, our research showed the following:
6/12 EW Report: Our research called out downward inflections in the US TAVR business with 100% filled data through the end of May.
7/15 EW Report: We published our 2Q U.S. TAVR estimate with fully settled June data, which caught the meaningful slowdown in TAVR’s performance during the last month of the quarter & drove our accurate below consensus call.
.webp)